By Sabela Ojea


AstraZeneca PLC said Friday that its Ultomiris drug has been approved in the European Union for the treatment of adults with the rare disease generalized myasthenia gravis.

The Anglo-Swedish pharma giant said that Ultomiris may reduce treatment burden with dosing every eight weeks, it said, adding that the drug also proved an improvement in activities of daily living.

Generalized myasthenia gravis is a rare autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness, AstraZeneca said.


Write to Sabela Ojea at; @sabelaojeaguix


(END) Dow Jones Newswires

September 23, 2022 02:27 ET (06:27 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 10 2022 まで 11 2022 Astrazenecaのチャートをもっと見るにはこちらをクリック
Astrazeneca (LSE:AZN)
過去 株価チャート
から 11 2021 まで 11 2022 Astrazenecaのチャートをもっと見るにはこちらをクリック